Bank Pictet & Cie Europe AG Sells 16,705 Shares of Abbott Laboratories $ABT

Key Points

• Bank Pictet & Cie Europe AG reduced its Abbott Laboratories stake by 34.6% in the second quarter, selling 16,705 shares and retaining 31,559 shares valued at approximately $2.86 million. Institutional investors collectively own 75.18% of Abbott’s stock.
• Wall Street remains broadly positive on Abbott, with a consensus “Moderate Buy” rating and an average price target of $118.67. The company recently exceeded quarterly earnings and revenue expectations, reporting $1.31 in EPS and $12.59 billion in revenue, with revenue up 13% year over year.
• Abbott is expanding its diabetes and diagnostics businesses through new sensor and testing partnerships, but agreed to pay approximately $670 million to resolve part of its infant-formula litigation, leaving investors to assess remaining legal exposure and profitability impacts.

Bank Pictet & Cie Europe AG cut its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 34.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,559 shares of the healthcare product maker's stock after selling 16,705 shares during the quarter. Bank Pictet & Cie Europe AG's holdings in Abbott Laboratories were worth $2,864,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. MidAtlantic Capital Management Inc. bought a new position in shares of Abbott Laboratories in the 4th quarter worth about $25,000. Cornerstone Financial Management LLC purchased a new position in shares of Abbott Laboratories during the fourth quarter valued at approximately $25,000. Purpose Unlimited Inc. bought a new stake in shares of Abbott Laboratories in the 4th quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. bought a new position in Abbott Laboratories during the 4th quarter valued at approximately $26,000. Finally, Abound Financial LLC purchased a new position in Abbott Laboratories during the fourth quarter valued at $26,000. Institutional investors own 75.18% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ABT shares. TD Cowen restated a "buy" rating and set a $115.00 price target on shares of Abbott Laboratories in a report on Friday, July 17th. BTIG Research raised their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a "buy" rating in a research note on Friday, July 17th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $130.00 target price on shares of Abbott Laboratories in a report on Friday, July 17th. Robert W. Baird started coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They set an "outperform" rating and a $121.00 price target on the stock. Finally, Wolfe Research upgraded shares of Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price objective for the company in a report on Thursday, August 13th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories has a consensus rating of "Moderate Buy" and an average target price of $118.67.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Instinct continuous glucose sensor is now commercially shipping in the U.S. integrated with MiniMed’s Flex automated insulin-delivery system. The partnership expands Abbott’s presence in diabetes technology and could support sensor adoption and recurring revenue. MiniMed Ships MiniMed Flex With Abbott's Smallest Instinct Sensor
• Positive Sentiment: Abbott also entered a multiyear agreement with HealthTab to distribute its Afinion 2 point-of-care analyzers through NHS-linked pharmacies in the United Kingdom. The deal may broaden access to Abbott’s HbA1c and lipid-testing products, although financial details were not disclosed. HealthTab Enters Multi-Year Collaboration Agreement with Abbott
• Neutral Sentiment: Abbott agreed to pay approximately $670 million to resolve the Gill case and claims from roughly 2,000 individuals involving specialty formulas for premature infants. The settlement resolves a portion of the litigation, including the appeal of a prior $495 million verdict, reducing uncertainty and potentially avoiding additional legal costs. Abbott denied that its products cause necrotizing enterocolitis and said regulators and medical professionals consider the formulas safe and necessary. Abbott agrees to $670 million settlement of infant formula cases
• Negative Sentiment: The settlement represents a significant cash and earnings cost and does not resolve all potential litigation related to the infant formulas. Investors may continue to assess the scope of remaining claims and the effect on Abbott’s legal reserves and profitability. Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas

Abbott Laboratories Stock Performance

NYSE:ABT opened at $116.62 on Friday. The stock has a 50-day simple moving average of $100.08 and a two-hundred day simple moving average of $100.05. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The firm has a market capitalization of $201.80 billion, a PE ratio of 37.74, a P/E/G ratio of 2.21 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the previous year, the firm earned $1.26 earnings per share. The company's revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts forecast that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. Abbott Laboratories's dividend payout ratio (DPR) is 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source